CN107158363A - 一种用于治疗***的修复液 - Google Patents
一种用于治疗***的修复液 Download PDFInfo
- Publication number
- CN107158363A CN107158363A CN201710344240.7A CN201710344240A CN107158363A CN 107158363 A CN107158363 A CN 107158363A CN 201710344240 A CN201710344240 A CN 201710344240A CN 107158363 A CN107158363 A CN 107158363A
- Authority
- CN
- China
- Prior art keywords
- present
- acid
- liquid
- growth factor
- rotten
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003628 erosive effect Effects 0.000 title claims abstract description 18
- 239000007788 liquid Substances 0.000 title claims abstract description 18
- 239000000843 powder Substances 0.000 claims abstract description 19
- 150000001413 amino acids Chemical class 0.000 claims abstract description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 10
- 239000002253 acid Substances 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 8
- 239000012153 distilled water Substances 0.000 claims abstract description 8
- 239000008103 glucose Substances 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims abstract description 8
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims abstract description 6
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims abstract description 6
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 claims abstract description 6
- 229940126864 fibroblast growth factor Drugs 0.000 claims abstract description 6
- 229940116978 human epidermal growth factor Drugs 0.000 claims abstract description 6
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 claims abstract description 6
- 239000011780 sodium chloride Substances 0.000 claims abstract description 5
- 235000001014 amino acid Nutrition 0.000 claims description 12
- 229940024606 amino acid Drugs 0.000 claims description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 4
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 229960003067 cystine Drugs 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- 229910021529 ammonia Inorganic materials 0.000 claims description 3
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract description 9
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract description 9
- 235000005822 corn Nutrition 0.000 abstract description 9
- 230000008439 repair process Effects 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 6
- 230000006378 damage Effects 0.000 abstract description 5
- 230000012010 growth Effects 0.000 abstract description 5
- 239000002775 capsule Substances 0.000 abstract description 2
- 238000011443 conventional therapy Methods 0.000 abstract description 2
- 238000011069 regeneration method Methods 0.000 abstract description 2
- 230000001835 salubrious effect Effects 0.000 abstract description 2
- 241000209149 Zea Species 0.000 abstract 2
- 210000003491 skin Anatomy 0.000 description 14
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 206010052428 Wound Diseases 0.000 description 7
- 240000008042 Zea mays Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010008342 Cervix carcinoma Diseases 0.000 description 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000010881 cervical cancer Diseases 0.000 description 4
- 208000019065 cervical carcinoma Diseases 0.000 description 4
- 231100000241 scar Toxicity 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000019522 cellular metabolic process Effects 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 201000005630 leukorrhea Diseases 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 206010046901 vaginal discharge Diseases 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100120045 Bos taurus FGF1 gene Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 229960002566 papillomavirus vaccine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及一种用于治疗***的修复液,其特征在于,是由以下重量百分比的物质调配制成:氯化钠,0.6~0.18%;氨基酸粉,1.2~6%;葡萄糖粉,3~12%;重组人表皮生长因子冻干粉,1.2~6%;酸性成纤维细胞生长因子冻干粉,1.2~6%;余量为蒸馏水。本发明中的治疗思路和常规治疗相反,不是让糜烂层面破坏脱落掉,而是让糜烂层面快速地自我修复生长,免去来手术的烦恼和弊端。本发明中修复液为中性,避免了传统药物对***菌群(酸碱平衡)的破坏,菌群越平衡生长修复的速度就越快。本发明中药液一次见效,并且使用完以后宫颈干净清爽,异味减少,轻微纳囊也会改善,连续使用一周糜烂二度可以转为一度,效果明显。
Description
技术领域
本发明涉及***治疗药物领域,具体涉及一种用于治疗***的修复液。
背景技术
据调查,我国女性的***发病率排世界第二,是发达国家的6倍。在中国每年约有15万新发***病例,约占全球患者总数的1/3,近8万妇女因此死去,***成中国女性的杀手之一。该问题十分严峻,同时还呈现出年轻化趋势,***发病平均年龄不断下降,10年间下降约5岁。宫颈疾病不仅摧残了数以万计女性的健康,还影响了中国千万家庭的幸福生活。我国政府虽然已在开展***筛查,但受经费和技术条件限制,因此每年受益人群其实有限,尤其相对于育龄妇女的庞大基数而言,可谓杯水车薪。
有专家呼吁,应加快***疫苗的研究推广,但国产疫苗还在研究之中,国外的***疫苗(HPV疫苗)也未在我国获批,中国妇女短期内难以获益。***应该早预防、早发现和早治疗。***有相当部分是由于***引起,***是一种常见的慢性严炎症,当它严重糜烂一定的时候就一定会有癌症的几率发生。
目前针对***的治疗大多采用手术和/或药物手段,目的都是通过技术手段将糜烂的表面部分去除掉,然后再在等其自行生长修复,而并非真正解决患者问题,时间久了一旦免疫力下降就立刻复发。因此才会导致今天大家所说的女性问题难以解决根治的问题。并且宫颈口在做完手术后生长出的是疤痕组织,其没有收缩性。同时一些药物也会对***菌群产生破坏性效果,长期用药物的人群都反馈***干涩,灼热,刺痛,无***。
发明内容
本发明要解决的技术问题是:提出一种无负作用,并且见效快的用于治疗***的修复液。
本发明为解决上述技术问题提出的技术方案是:一种用于治疗***的修复液,其特征在于,是由以下重量百分比的物质调配制成:
氯化钠,0 .6~0 .18%;
氨基酸粉,1.2~6%;
葡萄糖粉,3~12%;
重组人表皮生长因子冻干粉,1.2~6%;
酸性成纤维细胞生长因子冻干粉,1.2~6%;
余量为蒸馏水。
进一步的,所述氨基酸粉包括以下重量份的:天门冬氨酸 9.16、苏氨酸 2.81、丝氨酸 4.01、谷氨酸 14.7、脯氨酸 5.60、甘氨酸 4.88、丙氨酸 5.89、胱氨酸 0.94、缬氨酸4.21 、甲硫氨酸0.93、异亮氨酸2.97、亮氨酸6.11、酪氨酸2.12、苯丙氨酸4.56、赖氨酸5.64、组氨酸2.54、精氨酸3.84。
本发明的有益效果是:
本发明中的治疗思路和常规治疗相反,不是让糜烂层面破坏脱落掉,而是让糜烂层面快速地自我修复生长,免去来手术的烦恼和弊端。根据***的引起原因着手,先给宫颈彻底消炎排一些失调被感染的白带分泌物。当白带分泌物的东西被排出来以后,再通过本发明中修复液修复已经糜烂的部分让其快速长出来,修复糜烂长出新生层面,消除炎症。
同时本发明中修复液为中性,避免了传统药物对***菌群(酸碱平衡)的破坏,菌群越平衡生长修复的速度就越快。
本发明中药液一次见效,并且使用完以后宫颈干净清爽,异味减少,轻微纳囊也会改善, 连续使用一周糜烂二度可以转为一度,效果明显,痊愈效果99%。
具体实施方式
实施例1
本实施例中的用于治疗***的修复液,是由以下重量百分比的物质调配制成:
氯化钠,0 .6%;
氨基酸粉,1.2%;
葡萄糖粉,3%;
重组人表皮生长因子冻干粉,1.2%;
酸性成纤维细胞生长因子冻干粉,1.2%;
余量为蒸馏水。
可以作为优选的是:所述氨基酸粉包括以下重量份的:天门冬氨酸 9.16、苏氨酸2.81、丝氨酸 4.01、谷氨酸 14.7、脯氨酸 5.60、甘氨酸 4.88、丙氨酸 5.89、胱氨酸 0.94、缬氨酸4.21 、甲硫氨酸0.93、异亮氨酸2.97、亮氨酸6.11、酪氨酸2.12、苯丙氨酸4.56、赖氨酸5.64、组氨酸2.54、精氨酸3.84。
基本机理在于:
蒸馏水:清洗伤口,消炎,去脏污,蒸馏水的作用是因为低渗作用。用蒸馏水冲洗手术伤口,使创面可能残留的肿瘤细胞吸水膨胀,破裂,坏死,失去活性,避免肿瘤在创面种植生长。
氨基酸:是构建生物机体的众多生物活性大分子之一,是构建细胞、修复组织的基础材料。
葡萄糖:亦称糖类,是人体热能最主要的来源。它在人体内消化后,主要以葡萄糖的形式被吸收利用。葡萄糖能够迅速被氧化并提供(释放)能量碳水化合物与脂类形成的糖脂是组成细胞膜与神经组织的成分,糖类与蛋白质结合成糖蛋白可构成抗体、某些酶和激素等具有重要生物活性的物质。糖类具有节省蛋白质的作用。当蛋白质进入机体后,使组织中游离氨基酸浓度增加,该氨基酸合成为机体蛋白质是耗能过程,如同时摄入糖类补充能量,可节省一部分氨基酸,有利蛋白质合成。
重组人表皮生长因子(EGF):作为一种强有力的细胞***因子,具有多种生物活性,EGF具有修复表皮、抗衰老、淡化色斑、平复皱纹、滋润之功效,主要表现为:
1)在体内刺激皮肤组织、角膜和气管上皮组织的生长繁殖;
2)促进细胞再生和组织修复:EGF有促进皮肤和黏膜创伤面的愈合作用,并减少疤痕挛缩和皮肤畸形增生,加速角膜、皮肤等表皮创伤的修复。用于治疗疤痕,尤其是痤疮后留下的疤痕、疙瘩疗效较好;
3)嫩肤护肤作用:EGF能促进皮肤细胞对营养物质的吸收,加速细胞的新陈代谢,促进皮肤细胞的***和增长,促进透明质酸和糖蛋白的合成;
4)增强表皮细胞的蛋白质、DNA、RNA的合成和细胞代谢等。
酸性成纤维细胞生长因子(AFGF),具有针对真皮层(皮肤中层),主要诱导中胚层和神经外胚层发育和分化,改善细胞生成环境,促进胶原细胞、角质细胞、成纤维细胞增殖的作用。呈酸性,其生物活性和稳定性能优越。采用基因重组方式获得,与人体百分之百同源。能促进皮下微血管的新生、改善皮肤的血液循环,促使细胞代谢活跃并且有效清除造成代谢障碍的细胞,从而使细胞中各种有害的代谢产物不容易积累形成色斑,明显改善肤色。促进中胚层和神经外胚层来源的细胞生长,有效恢复皮下***的生长,使新生表皮细胞取代衰老的角质细胞,从而消除皮肤深层皱纹;促进成纤维母细胞分泌胞外基质、胶原蛋白,弹性纤维细胞分泌弹性蛋白,从而使表皮层与真皮层、真皮层与皮下组织之间结合组织中的网状层和胶原纤维增殖,回复肌肤原有的紧致和平滑,可以有效避免因皮肤松弛而出现皱纹。能促进成纤维细胞、胶原细胞、角质细胞等***增殖,而使深层次的损伤皮肤组织迅速修复,加速伤口愈合(比正常愈合速度快3-4倍),对皮肤组织的各种创伤或祛除暗疮、痤疮、去痣后的小缺损,换肤后的脱皮、发红等深层次肌肤损伤修复具有突出效果。
实施例二
本实施例中的用于治疗***的修复液,是由以下重量百分比的物质调配制成:
氯化钠, 0 .18%;
氨基酸粉, 6%;
葡萄糖粉, 12%;
重组人表皮生长因子冻干粉, 6%;
酸性成纤维细胞生长因子冻干粉, 6%;
余量为蒸馏水。
可以作为优选的是:所述氨基酸粉包括以下重量份的:天门冬氨酸 9.16、苏氨酸2.81、丝氨酸 4.01、谷氨酸 14.7、脯氨酸 5.60、甘氨酸 4.88、丙氨酸 5.89、胱氨酸 0.94、缬氨酸4.21 、甲硫氨酸0.93、异亮氨酸2.97、亮氨酸6.11、酪氨酸2.12、苯丙氨酸4.56、赖氨酸5.64、组氨酸2.54、精氨酸3.84。
使用方法:
通过推管将本发明中修复液推进***后用生理棉堵塞住以防流出,5小时后取出生理棉。
临床患例:
患例一,江苏扬州天资美容院客户,三十岁的张女士在超市做收银工作,在治疗前***二度。她认识到手术对身体的伤害,因此不要去医院做手术,而选择使用本发明中修复液进行治疗,结合治疗前、后一个小时的彩图对比显示***已经修复一度。进一步地通过一个月的持续治疗,现已康复。
患例二,江苏常州千千丝美容院客户,四十二岁,糜烂三度。在治疗前,打开并拍摄彩图发现其宫颈已经烂的很深,很红。客户本人描述说去医院看医生后拿了药用了一段时间没有见好转,自己也没有看到过,今天看到后才知道原来烂成这样。采纳我们建议的深度治疗方案,用双份量本发明中修复液进行治疗。在治疗后通过彩图对比,看到效果修复好到二度,客户很开心,再在后续的搭配治疗后已完全康复,用了两个月不到的时间。
本发明的不局限于上述实施例,本发明的上述各个实施例的技术方案彼此可以交叉组合形成新的技术方案,另外凡采用等同替换形成的技术方案,均落在本发明要求的保护范围内。
Claims (2)
1.一种用于治疗***的修复液,其特征在于,是由以下重量百分比的物质调配制成:
氯化钠,0 .6~0 .18%;
氨基酸粉,1.2~6%;
葡萄糖粉,3~12%;
重组人表皮生长因子冻干粉,1.2~6%;
酸性成纤维细胞生长因子冻干粉,1.2~6%;
余量为蒸馏水。
2.根据权利要求1所述用于治疗***的修复液,其特征在于,所述氨基酸粉包括以下重量份的:天门冬氨酸 9.16、苏氨酸 2.81、丝氨酸 4.01、谷氨酸 14.7、脯氨酸 5.60、甘氨酸 4.88、丙氨酸 5.89、胱氨酸 0.94、缬氨酸4.21 、甲硫氨酸0.93、异亮氨酸2.97、亮氨酸6.11、酪氨酸2.12、苯丙氨酸4.56、赖氨酸5.64、组氨酸2.54、精氨酸3.84。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710344240.7A CN107158363A (zh) | 2017-05-16 | 2017-05-16 | 一种用于治疗***的修复液 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710344240.7A CN107158363A (zh) | 2017-05-16 | 2017-05-16 | 一种用于治疗***的修复液 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107158363A true CN107158363A (zh) | 2017-09-15 |
Family
ID=59816398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710344240.7A Pending CN107158363A (zh) | 2017-05-16 | 2017-05-16 | 一种用于治疗***的修复液 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107158363A (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1524577A (zh) * | 2003-02-27 | 2004-09-01 | 珠海亿胜生物制药有限公司 | 碱性成纤维细胞生长因子膜剂及其制备方法 |
CN1788802A (zh) * | 2005-12-14 | 2006-06-21 | 温州医学院 | 促创伤修复生物海绵材料及其制备方法 |
CN101175512A (zh) * | 2005-05-13 | 2008-05-07 | 株式会社奈特克 | 促进皮肤再生的医疗组合物 |
CN101690802A (zh) * | 2009-09-29 | 2010-04-07 | 杨霞 | 宫颈粘膜诱导凝胶 |
CN101721682A (zh) * | 2009-11-10 | 2010-06-09 | 成都博发生物技术有限公司 | 重组人成纤维细胞生长因子7突变体在制备治疗***的药物中的应用 |
CN101780031A (zh) * | 2009-09-29 | 2010-07-21 | 杨霞 | 一种用于修复皮肤创面或宫颈粘膜的诱导凝胶 |
CN103182070A (zh) * | 2013-04-12 | 2013-07-03 | 江苏迪沃生物制品有限公司 | 一种外用组合物、制剂及其应用 |
CN105919926A (zh) * | 2016-06-29 | 2016-09-07 | 江苏开源康达医疗器械有限公司 | 一种卡波姆宫颈凝胶及其制备方法 |
-
2017
- 2017-05-16 CN CN201710344240.7A patent/CN107158363A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1524577A (zh) * | 2003-02-27 | 2004-09-01 | 珠海亿胜生物制药有限公司 | 碱性成纤维细胞生长因子膜剂及其制备方法 |
CN101175512A (zh) * | 2005-05-13 | 2008-05-07 | 株式会社奈特克 | 促进皮肤再生的医疗组合物 |
CN1788802A (zh) * | 2005-12-14 | 2006-06-21 | 温州医学院 | 促创伤修复生物海绵材料及其制备方法 |
CN101690802A (zh) * | 2009-09-29 | 2010-04-07 | 杨霞 | 宫颈粘膜诱导凝胶 |
CN101780031A (zh) * | 2009-09-29 | 2010-07-21 | 杨霞 | 一种用于修复皮肤创面或宫颈粘膜的诱导凝胶 |
CN101721682A (zh) * | 2009-11-10 | 2010-06-09 | 成都博发生物技术有限公司 | 重组人成纤维细胞生长因子7突变体在制备治疗***的药物中的应用 |
CN103182070A (zh) * | 2013-04-12 | 2013-07-03 | 江苏迪沃生物制品有限公司 | 一种外用组合物、制剂及其应用 |
CN105919926A (zh) * | 2016-06-29 | 2016-09-07 | 江苏开源康达医疗器械有限公司 | 一种卡波姆宫颈凝胶及其制备方法 |
Non-Patent Citations (2)
Title |
---|
许华等: "重组人酸性成纤维细胞生长因子复方喷剂治疗***临床研究", 《新乡医学院学报》 * |
马常明等: "机械磨削联合微针导入重组人酸性成纤维细胞生长因子和基因重组人表皮生长因子促进创面愈合的临床观察", 《中国全科医学》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021184828A5 (zh) | ||
CN111110623A (zh) | 自体修复小小针营养液配方 | |
CN109893542A (zh) | 用于治疗***功能障碍的干细胞外泌体浓缩液凝胶制剂及其制备方法与给药方法 | |
TWI522131B (zh) | 具有間質幹細胞條件培養基之微膠囊結構於促進表皮細胞再生、血管新生、表皮細胞損傷修復及肌肉損傷修復功能之用途 | |
CN101152568A (zh) | 具有促进血管形成、组织再生及伤口愈合作用的多肽组合制剂 | |
CN101648018A (zh) | 一种治疗眼科炎症的中药组合物及其用途 | |
CN108743921A (zh) | 一种预防疤痕形成的修复液及其制备方法和应用 | |
CN106344435A (zh) | 消除妊娠纹的护肤膏 | |
US20210046161A1 (en) | Skin ointment for treating labia minora skin | |
CN107158363A (zh) | 一种用于治疗***的修复液 | |
CN103520708A (zh) | 一种能促进创伤愈合、减少疤痕形成的组合物 | |
CN109646671B (zh) | 一种生长因子制剂及其制备方法和应用 | |
CN106563121B (zh) | 重组牛碱性成纤维细胞生长因子凝胶在修复玫瑰痤疮皮损中的应用 | |
CN103690393A (zh) | 美白抗皱生物蚕丝面膜 | |
Matthews-Brzozowska et al. | Revitalization of facial skin based on preparations of patient own blood | |
CN101057823B (zh) | 一种具有抗衰老及美容作用的复合生物制剂 | |
CN106176271A (zh) | 面膜剂料 | |
CN107551090A (zh) | 一种滋养修复凝胶 | |
CN104667262B (zh) | 重组牛碱性成纤维细胞生长因子外用溶液 | |
CN108289934A (zh) | 用于伤口愈合的纤溶酶原给药方案 | |
KR20120009183A (ko) | 인간 중간엽줄기세포의 분화 촉진용 조성물 | |
CN1330371C (zh) | 一种重组人表皮生长因子复合生物制剂及其应用 | |
CN110624102A (zh) | 贝复新作为修复蠕形螨病皮损中的药在临床中的应用 | |
CN102362856B (zh) | 重组牛碱性成纤维细胞生长因子外用溶液 | |
CN101380421B (zh) | 一种治疗白癜风的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170915 |
|
RJ01 | Rejection of invention patent application after publication |